This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Ishihara Sangyo Kaisha, Ltd.. Active years: 1992.
Company Filing History:
Years Active: 1992
Title: Taiji Katayama: Innovator in Antitumorous and Antibacterial Agents
Introduction
Taiji Katayama, a prominent inventor based in Kusatsu, Japan, has made significant strides in the field of medicinal chemistry. With a focus on developing compounds that exhibit antitumorous and antibacterial properties, his work contributes to advancements in therapeutic solutions for various health conditions.
Latest Patents
Katayama holds a patent for "Exo-3',4'-O-benzylidene-3'-demethylchartreusin and its salts - Exo-3',4'-O-benzylidene-3'-dimethylchartreusin (exo-BDMC) or its salts and 3'-demethylchartreusin (3'-DMC) or its salts." This patent outlines the utility of Exo-BDMC and its salts as effective antitumorous and antibacterial agents, while 3'-DMC and its salts serve as starting materials for producing exo-BDMC. This innovative approach showcases his commitment to addressing critical medical challenges through chemical innovation.
Career Highlights
Working at Ishihara Sangyo Kaisha, Ltd., Katayama has utilized his expertise to develop new pharmaceutical agents. His dedication to research and innovation has established him as a key figure in his organization, known for pushing the boundaries of medicinal applications through unique chemical compounds.
Collaborations
Throughout his career, Katayama has collaborated with esteemed colleagues, including Nobutoshi Yamada and Hideo Sugi. These partnerships have fostered a creative environment, enabling the exchange of ideas and catalyzing significant advancements in their shared projects.
Conclusion
Taiji Katayama's contributions to the field of medicinal chemistry, particularly in the development of antitumorous and antibacterial agents, reflect the essence of innovation in healthcare. His work not only illustrates the importance of collaboration within research institutions but also highlights the ongoing need for innovative solutions to pressing medical issues.